# Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB

> **NCT03085758** · PHASE2 · COMPLETED · sponsor: **Adrenomed AG** · enrollment: 301 (actual)

## Conditions studied

- Septic Shock

## Interventions

- **BIOLOGICAL:** Adrecizumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03085758
- **Lead sponsor:** Adrenomed AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-12
- **Primary completion:** 2019-12-20
- **Final completion:** 2019-12-20
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2024-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03085758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03085758, "Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03085758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*